These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8779031)

  • 1. [Effect of chemotherapy on hematopoietic stem cells in peripheral blood].
    Nieto MJ; Cañizo C; Corral M; Almeida J; San Miguel J
    Sangre (Barc); 1996 Feb; 41(1):29-35. PubMed ID: 8779031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression.
    Villaron EM; Almeida J; Lopez-Holgado N; Sanchez-Guijo FM; Alberca M; Blanco B; Sanchez-Abarca LI; Lopez O; Perez-Simon JA; San Miguel JF; del Cañizo MC
    Transfus Apher Sci; 2007 Oct; 37(2):145-56. PubMed ID: 17983836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation.
    del Cañizo C; Lopez N; Caballero D; Fernandez E; Brufau A; Vazquez L; Mateos V; Gutierrez N; San Miguel JF
    Bone Marrow Transplant; 1999 May; 23(9):901-5. PubMed ID: 10338045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro assessment of bone marrow endothelial colonies (CFU-En) in non-Hodgkin's lymphoma patients undergoing peripheral blood stem cell transplantation.
    Lanza F; Campioni D; Punturieri M; Moretti S; Dabusti M; Spanedda R; Castoldi G
    Bone Marrow Transplant; 2003 Dec; 32(12):1165-73. PubMed ID: 14647271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood stem cells mobilized from patients with acute myeloid leukaemia have different platelet repopulating abilities compared with those mobilized from patients with other diseases.
    Roberts MM; Dyson PG; Willson K; Juttner CA; To LB
    Bone Marrow Transplant; 1996 Jul; 18(1):41-5. PubMed ID: 8831994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors affecting mobilization and peripheral blood stem cell (PBSC) collection using single apheresis (SA) for rescuing patients after high-dose chemotherapy (HD.CHE) in various malignancies.
    Koumakis G; Vassilomanolakis M; Hatzichristou H; Barbounis V; Filis J; Papanastasiou K; Moraki M; Kritsioti M; Plataniotis G; Stamatelou M; Efremidis AP
    Bone Marrow Transplant; 1996 Dec; 18(6):1065-72. PubMed ID: 8971374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection.
    Corso A; Varettoni M; Mangiacavalli S; Zappasodi P; Klersy C; Rusconi C; Colucci E; Lorenzi A; Troletti D; Consensi E; Lazzarino M
    Leuk Res; 2005 Feb; 29(2):159-63. PubMed ID: 15607364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
    Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between hematopoietic progenitor cell counts as measured by Sysmex and CD34+ cell harvest yields following mobilization with different regimens.
    Vogel W; Kopp HG; Kanz L; Einsele H
    J Cancer Res Clin Oncol; 2002 Jul; 128(7):380-4. PubMed ID: 12136252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Kim S; Kim HJ; Park JS; Lee J; Chi HS; Park CJ; Huh J; Suh C
    Ann Hematol; 2005 Oct; 84(11):742-7. PubMed ID: 16132903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
    Seropian S; Nadkarni R; Jillella AP; Salloum E; Burtness B; Hu GL; Zelterman D; Cooper DL
    Bone Marrow Transplant; 1999 Mar; 23(6):599-605. PubMed ID: 10217191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors.
    Carlo-Stella C; Tabilio A; Regazzi E; Garau D; La Tagliata R; Trasarti S; Andrizzi C; Vignetti M; Meloni G
    Bone Marrow Transplant; 1997 Sep; 20(6):465-71. PubMed ID: 9313879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
    Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.